A New Chapter for BioTissue: Sharpening Our Focus on Ocular Care

Last week, BioTissue® announced the sale of its non-ocular surgical business to BioStem Technologies, Inc. This strategic decision marks an important milestone in our journey—and it reflects a clear vision for the future: to focus exclusively on advancing Ocular care. 

Since our founding by Amy Tseng and Dr. Scheffer Tseng, an ophthalmologist, Ocular care has been at the heart of the BioTissue brand. Our mission has always been to help eye care professionals deliver exceptional outcomes for their patients. Today, that commitment is stronger than ever. 

Building on a Strong Foundation 

Over the past few years, we’ve taken deliberate steps to deepen our support for ophthalmologists, optometrists, and their patients: 

• Expanded Our Field Sales Team
  We’ve grown a team dedicated to delivering best-in-class expertise and service, ensuring our customers have the support they need when they need it. 

• Introduced CAM360 AmnioGraft™ in 2024
  Developed for patient comfort, this advancement expanded our Cryopreserved Amniotic Membrane portfolio (Prokera®, AmnioGraft®, and AmnioGuard®), giving eye care professionals more choice and flexibility in interventional therapy. https://biotissue.com/products/ocular/cam360-amniograft/ 

• Established Our First Medical Advisory Board in 2025
  Bringing together leading ophthalmologists and optometrists, this board is helping accelerate the development and adoption of evidence-based biologic solutions for ocular surface disease—while providing invaluable insights into customer needs. https://biotissue.com/about-us/medical-advisory-board/

Looking Ahead 

With this divestiture, we now have a singular focus: to realize the full potential of regenerative therapy in Ocular care. This clarity allows us to move faster, invest more deeply, and innovate with purpose—always guided by the needs of the eye care community. 

We’re excited about what’s ahead and invite you to join us on this journey. Together, we can redefine what’s possible for patients and practices everywhere. 

I would be remiss if I did not express my gratitude to our former Surgical and Wound Care sales and support teams. I am excited to see this talented group thrive and make a difference at BioStem. 

Thank you for your trust and partnership. 

Sincerely, 

Ted Davis, President and CEO